1. Targeting <scp>ASCT2</scp> ‐mediated glutamine uptake blocks prostate cancer growth and tumour development
- Author
-
Michelle van Geldermalsen, Charles G. Bailey, Andrew J. Hoy, Natalia Pinello, John E.J. Rasko, Martin E. Gleave, Nicholas J. Otte, Colleen C. Nelson, Martin C. Sadowski, Rae-Anne Hardie, Qian Wang, Dadi Gao, Seher Balaban, Justin J.-L. Wong, Mark Schreuder, Ladan Fazli, William Ritchie, Cynthia Metierre, Rajini Nagarajah, Melanie Lehman, and Jeff Holst
- Subjects
Amino Acid Transport System ASC ,Male ,SLC1A5 ,Cell Cycle Pathway ,Glutamine ,Cell ,Down-Regulation ,Mice, Nude ,Mechanistic Target of Rapamycin Complex 1 ,Biology ,Pathology and Forensic Medicine ,Minor Histocompatibility Antigens ,Mice ,chemistry.chemical_compound ,Cell Line, Tumor ,LNCaP ,medicine ,Animals ,Humans ,Neoplasm Metastasis ,RNA, Small Interfering ,Cell Proliferation ,Original Paper ,Cell growth ,TOR Serine-Threonine Kinases ,Cell Cycle ,Fatty Acids ,Prostatic Neoplasms ,Biological Transport ,Cell cycle ,prostate cancer ,Original Papers ,ASCT2 ,3. Good health ,Gene Expression Regulation, Neoplastic ,Oxygen ,medicine.anatomical_structure ,Biochemistry ,chemistry ,Gene Knockdown Techniques ,Multiprotein Complexes ,Cancer cell ,Cancer research ,Heterografts ,Anaplerotic reactions ,metabolism - Abstract
Glutamine is conditionally essential in cancer cells, being utilized as a carbon and nitrogen source for macromolecule production, as well as for anaplerotic reactions fuelling the tricarboxylic acid (TCA) cycle. In this study, we demonstrated that the glutamine transporter ASCT2 (SLC1A5) is highly expressed in prostate cancer patient samples. Using LNCaP and PC‐3 prostate cancer cell lines, we showed that chemical or shRNA‐mediated inhibition of ASCT2 function in vitro decreases glutamine uptake, cell cycle progression through E2F transcription factors, mTORC1 pathway activation and cell growth. Chemical inhibition also reduces basal oxygen consumption and fatty acid synthesis, showing that downstream metabolic function is reliant on ASCT2‐mediated glutamine uptake. Furthermore, shRNA knockdown of ASCT2 in PC‐3 cell xenografts significantly inhibits tumour growth and metastasis in vivo, associated with the down‐regulation of E2F cell cycle pathway proteins. In conclusion, ASCT2‐mediated glutamine uptake is essential for multiple pathways regulating the cell cycle and cell growth, and is therefore a putative therapeutic target in prostate cancer. © 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
- Published
- 2015
- Full Text
- View/download PDF